A. Ekström, Update on HIV pandemic, Retrovirology, vol.9, issue.Suppl 1, p.4
DOI : 10.1186/1742-4690-9-S1-I4

U. Who and . Unicef, Global HIV/AIDS response -Epidemic update and health sector progress towards universal access, 2011.

S. Rosen and M. Fox, Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review, PLoS Medicine, vol.15, issue.7, p.1001056, 2011.
DOI : 10.1371/journal.pmed.1001056.s002

L. Juárez-figueroa, A. González-rodríguez, and E. Rodríguez-nolasco, Integral HIV-STI diagnosis at the first VCT visit as strategy to prevent late ART initiation in the HIV-AIDS program of Mexico City (HIVPMC), Retrovirology, vol.9, issue.Suppl 1, p.73
DOI : 10.1186/1742-4690-9-S1-P73

U. Who, The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support, 2011.

S. Fahim, S. Shastri, and R. Washington, Scaling up HIV treatment -Karnataka, India experience, Retrovirology, vol.9, issue.Suppl 1, p.71
DOI : 10.1186/1742-4690-9-S1-P71

S. Fahim, S. Shastri, and B. Rewari, Decentralizing treatment services with link ART centres- experience from Karnataka, South India, Retrovirology, vol.9, issue.Suppl 1, p.82
DOI : 10.1186/1742-4690-9-S1-P82

S. Grigoryan and A. Mkrtchyan, Access to HIV treatment and care in Armenia, Retrovirology, vol.9, issue.Suppl 1, p.75
DOI : 10.1186/1742-4690-9-S1-P75

R. Granich, J. Kahn, R. Bennett, C. Holmes, and N. Garg, Expanding ART for Treatment and Prevention of HIV in South Africa: Estimated Cost and Cost-Effectiveness 2011-2050, PLoS ONE, vol.371, issue.17, p.30216, 2011.
DOI : 10.1371/journal.pone.0030216.s001

C. Sloan, K. Champenois, P. Choisy, E. Losina, and R. Walensky, Newer drugs and earlier treatment, AIDS, vol.26, issue.1, pp.45-56
DOI : 10.1097/QAD.0b013e32834dce6e

Y. Yazdanpanah, C. Sloan, C. Charlois-ou, L. Vu, S. Semaille et al., Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness, PLoS ONE, vol.5, issue.10, p.13132, 2010.
DOI : 10.1371/journal.pone.0013132.s001

A. Paltiel, K. Freedberg, C. Scott, B. Schackman, and E. Losina, HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost???Effectiveness, Clinical Infectious Diseases, vol.48, issue.6, pp.806-815, 2009.
DOI : 10.1086/597095

J. Cohen, HIV Treatment as Prevention, Science, vol.334, issue.6063, p.1628, 2011.
DOI : 10.1126/science.334.6063.1628

J. Lange, "Test and Treat": Is It Enough?, Clinical Infectious Diseases, vol.52, issue.6, pp.801-802, 2011.
DOI : 10.1093/cid/ciq254

E. Gardner, M. Mclees, J. Steiner, D. Rio, C. Burman et al., The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection, Clinical Infectious Diseases, vol.52, issue.6, pp.793-800, 2011.
DOI : 10.1093/cid/ciq243

M. Wainberg, Pre-exposure prophylaxis against HIV: pros and cons, Retrovirology, vol.9, issue.Suppl 1, p.6
DOI : 10.1186/1742-4690-9-S1-I6

S. Abdool-karim and Q. Abdool-karim, Antiretroviral prophylaxis: a defining moment in HIV control, The Lancet, vol.378, issue.9809, pp.23-25, 2011.
DOI : 10.1016/S0140-6736(11)61136-7

G. Silvestri, Animal models of functional HIV cure, Retrovirology, vol.9, issue.Suppl 1, p.9
DOI : 10.1186/1742-4690-9-S1-I9

C. Van-lint, Molecular control of HIV - 1 postintegration latency: implications for therapeutic strategies, Retrovirology, vol.9, issue.Suppl 1, p.10
DOI : 10.1186/1742-4690-9-S1-I10

T. Chun, Towards a cure for HIV: a long road ahead, Retrovirology, vol.9, issue.Suppl 1, p.12
DOI : 10.1186/1742-4690-9-S1-I12

R. Geleziunas, G. Stepan, and G. Wei, Search for small molecule activators of latent HIV, Retrovirology, vol.9, issue.Suppl 1, p.2
DOI : 10.1186/1742-4690-9-S1-O2

L. Shan, K. Deng, and N. Shroff, Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation, Immunity, vol.36, issue.3, pp.491-501, 2012.
DOI : 10.1016/j.immuni.2012.01.014

G. Mousseau, M. Clementz, M. Bakeman, and W. , Potent suppression of HIV viral replication by a novel inhibitor of Tat, Retrovirology, vol.9, issue.Suppl 1, p.11
DOI : 10.1186/1742-4690-9-S1-O11

H. Rafati, Y. Moshkin, and T. Mahmoudi, New transcription regulatory mechanisms of latent HIV LTR, Retrovirology, vol.9, issue.Suppl 1, p.3
DOI : 10.1186/1742-4690-9-S1-O3

S. Moreno, Anti-latency agents to purge HIV reservoirs, Retrovirology, vol.9, issue.Suppl 1, p.16
DOI : 10.1186/1742-4690-9-S1-I16

M. Stevenson, A roadmap to a cure, Retrovirology, vol.9, issue.Suppl 1, p.11
DOI : 10.1186/1742-4690-9-S1-I11

J. Pawlotsky, New antiviral agents for hepatitis C. F1000, Biol Rep, vol.4, issue.5, 2012.

D. Back, New drug interactions in HIV and HCV, Retrovirology, vol.9, issue.Suppl 1, p.8
DOI : 10.1186/1742-4690-9-S1-I8

S. Vella, B. Schwartländer, S. Sow, S. Eholie, and R. Murphy, The history of antiretroviral therapy and of its implementation in resource-limited areas of the world, AIDS, vol.26, issue.10, pp.1231-1241
DOI : 10.1097/QAD.0b013e32835521a3

J. Rockstroh, Managing antiretrovirals in co-infected patients in 2012, Retrovirology, vol.9, issue.Suppl 1, p.1
DOI : 10.1186/1742-4690-9-S1-I1

M. Arab-alameddine, L. Décosterd, T. Buclin, A. Telenti, and C. Csajka, Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics, Expert Opinion on Drug Metabolism & Toxicology, vol.9, issue.5, 2011.
DOI : 10.1038/clpt.2009.12

C. Goujard and H. Primary, infection: the French experience, Retrovirology, vol.2012, issue.9 1, p.14

J. Routy, Treating since the beginning?, Retrovirology, vol.9, issue.Suppl 1, p.15
DOI : 10.1186/1742-4690-9-S1-I15

M. Strain, S. Little, and E. Daar, Effect of Treatment, during Primary Infection, on Establishment and Clearance of Cellular Reservoirs of HIV-1, The Journal of Infectious Diseases, vol.191, issue.9
DOI : 10.1086/428777

S. Pol, What happens after hepatitis C eradication?, Retrovirology, vol.9, issue.Suppl 1, p.19
DOI : 10.1186/1742-4690-9-S1-I19

H. Lin, S. Lee, and M. Yu, Epidemiology of Hepatitis Delta Virus infection in HIV-infected individuals in Taiwan, Retrovirology, vol.9, issue.Suppl 1, p.49
DOI : 10.1186/1742-4690-9-S1-P49

V. Soriano, P. Barreiro, E. Vispo, P. Labarga, and V. Soriano, Management and Treatment of Chronic Hepatitis C in HIV Patients, Semin Liver Dis, vol.2012, issue.322, pp.138-146, 2012.

V. Soriano, S. Zeuzem, and F. Zoulim, Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?, Journal of Antimicrobial Chemotherapy, vol.62, issue.1, pp.1-4, 2008.
DOI : 10.1093/jac/dkn175

M. Cevik, G. Singh, and L. Dickinson, Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals, Retrovirology, vol.2012, issue.9 1, p.7

P. Andre, Hepatitis C as a metabolic disease, Retrovirology, vol.9, issue.Suppl 1, pp.10-1186
DOI : 10.1186/1742-4690-9-S1-I17